Juan Zhang, Jing Kan, Yongyue Wei, Caojin Zhang, Zhenwen Yang, Heping Gu, Fenling Fan, Hong Gu, Qiguang Wang, Dujiang Xie, Gangcheng Zhang, Xiaomei Guo, Yuehui Yin, Bowen Jin, Hongmei Zhou, Ziyang Yang, Zhouming Wang, Yu Xin, Chen Zhang, Lili Meng, Xiaoyu Wang, Chunxia Zhao, Hang Zhang, Xiaoyan Yan, Feng Chen, Cheng Yao, Raymond L Benza, Gregg W Stone, Shao-Liang Chen
BACKGROUND: The differential treatment effect of pulmonary artery denervation (PADN) in pulmonary arterial hypertension (PAH) patients with different risk burdens remains unclear. This study aimed to determine the effectiveness of PADN in low vs. intermediate-high-risk PAH patients. METHODS: In total, 128 patients with treatment naive PAH included in the PADN-CFDA trial were categorized into low-risk and intermediate-high-risk patients. The primary endpoint was the between-group difference in the change in 6-minute walk distance (6 MWD) from baseline to 6 months...
March 27, 2023: Journal of Heart and Lung Transplantation